myTomorrows announced it has raised $29 million in new growth funding from Avego to scale its AI-enabled platform that connects patients, physicians, trial sites, and BioPharma partners to pre-approval treatments. The company stated that the investment will expand its international reach, enhance platform capabilities, and strengthen collaborations across the pharmaceutical ecosystem.
The company addresses a gap in global healthcare where more than 300 million patients worldwide face conditions without approved treatments, despite over 10,000 therapies being actively developed or awaiting approval. myTomorrows enables access to pre-approval treatment pathways, such as clinical trials and expanded access programs, by connecting stakeholders and guiding patients and physicians through eligibility and access processes.
The new financing will support the company’s continued global growth of its AI-powered platform, which integrates patient and physician navigation services, real-time referral management for trial sites, and access and data solutions for BioPharma partners. The company noted that enhancing data capabilities will also help improve evidence generation and regulatory insights.
myTomorrows has facilitated access to treatments for over 16,900 patients across 133 countries, working with more than 2,800 physicians and over 340 trial sites. The platform supports clinical trial recruitment, expanded access program management, and real-world data collection to help accelerate drug development timelines.
The company stated that this new phase of growth builds on its mission to provide a more straightforward and transparent route for patients to access emerging therapies, regardless of location or healthcare system structure. The organization positions itself as an infrastructure for global pre-approval access and as a partner to biopharmaceutical companies developing innovative therapies that require broad and timely patient engagement.
The company is headquartered in Amsterdam, with an office in New York City.
KEY QUOTES:
“This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow’s therapies.”
Michel van Harten, CEO, myTomorrows
“Avego is proud to support myTomorrows in its mission to transform how patients and physicians access therapies in development. We believe myTomorrows is uniquely positioned to remove barriers for patients and providers while serving as an essential partner to BioPharma.”
James Flexner, Managing Partner, Avego
“When we founded myTomorrows in 2012, we envisioned a better way to connect patients with promising therapies one that complements drug development and expands access to innovation. This investment marks the beginning of a next phase of accelerated growth and worldwide impact.”
Ronald Brus, Founder and Board Member, myTomorrows
